| Literature DB >> 28978426 |
Ruud S Kootte1, Evgeni Levin2, Jarkko Salojärvi3, Loek P Smits4, Annick V Hartstra4, Shanti D Udayappan4, Gerben Hermes5, Kristien E Bouter4, Annefleur M Koopen4, Jens J Holst6, Filip K Knop7, Ellen E Blaak8, Jing Zhao4, Hauke Smidt5, Amy C Harms9, Thomas Hankemeijer9, Jacques J G H M Bergman10, Hans A Romijn11, Frank G Schaap12, Steven W M Olde Damink12, Mariette T Ackermans13, Geesje M Dallinga-Thie4, Erwin Zoetendal5, Willem M de Vos14, Mireille J Serlie15, Erik S G Stroes4, Albert K Groen1, Max Nieuwdorp16.
Abstract
The intestinal microbiota has been implicated in insulin resistance, although evidence regarding causality in humans is scarce. We therefore studied the effect of lean donor (allogenic) versus own (autologous) fecal microbiota transplantation (FMT) to male recipients with the metabolic syndrome. Whereas we did not observe metabolic changes at 18 weeks after FMT, insulin sensitivity at 6 weeks after allogenic FMT was significantly improved, accompanied by altered microbiota composition. We also observed changes in plasma metabolites such as γ-aminobutyric acid and show that metabolic response upon allogenic FMT (defined as improved insulin sensitivity 6 weeks after FMT) is dependent on decreased fecal microbial diversity at baseline. In conclusion, the beneficial effects of lean donor FMT on glucose metabolism are associated with changes in intestinal microbiota and plasma metabolites and can be predicted based on baseline fecal microbiota composition.Entities:
Keywords: fecal microbiota transplantation; insulin sensitivity; intestinal microbiota composition; plasma metabolites
Mesh：
Substances：
Year: 2017 PMID： 28978426 DOI： 10.1016/j.cmet.2017.09.008
Source DB: PubMed Journal: Cell Metab ISSN： 1550-4131 Impact factor: 27.287